To reduce IOP in your patients with
open-angle glaucoma or ocular hypertension

Summery

In clinical studies of up to 1-year duration, in patients with
an average baseline IOP of 26.7 mmHg, VYZULTA® had
an IOP-lowering effect of up to 7 to 9 mmHg1

Summery

6% conjunctival hyperemia reported as
the most common ocular adverse reaction.Other most common ocular adverse reactions included eye irritation (5%), eye pain (4%),and
instillation site pain (2%)1

Summery

In the pooled results of APOLLO and LUNAR, a 33% IOP reduction from baseline following 3 months of treatment with VYZULTA® was demonstrated compared to 28% IOP reduction from baseline for those treated with timolol maleate (Month 3, 4 PM evaluation timepoint, p<0.001)1

Patients with open-angle glaucoma or ocular hypertension enrolled in APOLLO and LUNAR had combined average diurnal baseline IOPs of 26.7 mmHg in the VYZULTA® group and 26.5 mmHg in the timolol maleate 0.5% group.

Summery

Demonstrated a tolerable safety profile: Ocular effects comparable to those of the first-line agent latanoprost and no significant systemic effects1

ONE ACTIVE MOLECULE DropTWO ROUTES†

VYZULTA® is thought to lower IOP by increasing outflow of aqueous humor
through both uveoscleral and trabecular meshwork routes1†